PRELUDE THERAPEUTICS INC Net Income
PRELUDE THERAPEUTICS INC (PRLD) reported Net Income of -$13.92 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLoss · last filed 2026-08-11
- PRELUDE THERAPEUTICS INC net income (loss) attributable to parent for the quarter ending 2026-06-30 was -$13.92M.
- PRELUDE THERAPEUTICS INC net income (loss) attributable to parent for the quarter ending 2026-03-31 was -$10.38M.
- PRELUDE THERAPEUTICS INC net income (loss) attributable to parent for the quarter ending 2025-12-31 was -$16.46M.
- PRELUDE THERAPEUTICS INC net income (loss) attributable to parent for the quarter ending 2025-09-30 was -$19.73M.
- PRELUDE THERAPEUTICS INC net income (loss) attributable to parent for fiscal 2023 was -$121.83M.
- PRELUDE THERAPEUTICS INC net income (loss) attributable to parent for fiscal 2022 was -$115.44M.
- PRELUDE THERAPEUTICS INC net income (loss) attributable to parent for fiscal 2021 was -$111.69M.
- PRELUDE THERAPEUTICS INC net income (loss) attributable to parent for fiscal 2020 was -$56.93M.
| Period end | Net Income (Loss) Attributable to Parent 3 month | Net Income (Loss) Attributable to Parent 6 month | Net Income (Loss) Attributable to Parent 9 month | Net Income (Loss) Attributable to Parent 12 month | Net Income (Loss) Attributable to Parent 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | -$13.92M 10-Q · filed 2026-08-11 | -$24.31M 10-Q · filed 2026-08-11 | -$40.77M derived: sum of 3 quarters · filed 2026-08-11 | -$60.49M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2026-03-31 | -$10.38M 10-Q · filed 2026-08-11 | -$26.84M derived: sum of 2 quarters · filed 2026-08-11 | -$46.57M derived: sum of 3 quarters · filed 2026-08-11 | -$77.80M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-12-31 | -$16.46M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-29 | -$36.18M derived: sum of 2 quarters · filed 2026-04-29 | -$67.42M derived: sum of 3 quarters · filed 2026-08-11 | -$99.50M DEF 14A · filed 2026-04-29 | -$99.50M 10-K · filed 2026-03-10 |
| 2025-09-30 | -$19.73M 10-Q · filed 2025-11-12 | -$50.96M derived: sum of 2 quarters · filed 2026-08-11 | -$83.04M 10-Q · filed 2025-11-12 | -$111.77M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-06-30 | -$31.23M 10-Q · filed 2026-08-11 | -$63.32M 10-Q · filed 2026-08-11 | -$92.04M derived: sum of 3 quarters · filed 2026-08-11 | -$124.31M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-03-31 | -$32.09M 10-Q · filed 2026-08-11 | -$60.81M derived: sum of 2 quarters · filed 2026-08-11 | -$93.08M derived: sum of 3 quarters · filed 2026-08-11 | -$127.82M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2024-12-31 | -$28.73M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-29 | -$61.00M derived: sum of 2 quarters · filed 2026-04-29 | -$95.74M derived: sum of 3 quarters · filed 2026-04-29 | -$127.17M DEF 14A · filed 2026-04-29 | -$127.17M 10-K · filed 2025-03-10 |
| 2024-09-30 | -$32.27M 10-Q · filed 2025-11-12 | -$67.01M derived: sum of 2 quarters · filed 2025-11-12 | -$98.44M 10-Q · filed 2025-11-12 | -$131.52M derived: sum of 4 quarters · filed 2025-11-12 | |
| 2024-06-30 | -$34.74M 10-Q · filed 2025-11-12 | -$66.17M 10-Q · filed 2025-08-14 | -$99.25M derived: sum of 3 quarters · filed 2025-11-12 | -$129.85M derived: sum of 4 quarters · filed 2025-11-12 | |
| 2024-03-31 | -$31.43M 10-Q · filed 2025-11-12 | -$64.51M derived: sum of 2 quarters · filed 2025-11-12 | -$95.11M derived: sum of 3 quarters · filed 2025-11-12 | -$125.55M derived: sum of 4 quarters · filed 2025-11-12 | |
| 2023-12-31 | -$33.08M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | -$63.68M derived: sum of 2 quarters · filed 2025-03-10 | -$94.11M derived: sum of 3 quarters · filed 2025-03-10 | -$121.83M 10-K · filed 2025-03-10 | |
| 2023-09-30 | -$30.61M 10-Q · filed 2024-11-06 | -$61.04M derived: sum of 2 quarters · filed 2024-11-06 | -$88.76M 10-Q · filed 2024-11-06 | -$117.40M derived: sum of 4 quarters · filed 2024-11-06 | |
| 2023-06-30 | -$30.43M 10-Q · filed 2024-11-06 | -$58.15M 10-Q · filed 2024-08-12 | -$86.79M derived: sum of 3 quarters · filed 2024-11-06 | -$116.75M derived: sum of 4 quarters · filed 2024-11-06 | |
| 2023-03-31 | -$27.72M 10-Q · filed 2024-11-06 | -$56.36M derived: sum of 2 quarters · filed 2024-11-06 | -$86.32M derived: sum of 3 quarters · filed 2024-11-06 | -$113.69M derived: sum of 4 quarters · filed 2024-11-06 | |
| 2022-12-31 | -$28.64M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | -$58.60M derived: sum of 2 quarters · filed 2024-02-15 | -$85.97M derived: sum of 3 quarters · filed 2024-02-15 | -$115.44M 10-K · filed 2024-02-15 | |
| 2022-09-30 | -$29.96M 10-Q · filed 2023-11-01 | -$57.33M derived: sum of 2 quarters · filed 2023-11-01 | -$86.80M 10-Q · filed 2023-11-01 | -$119.64M derived: sum of 4 quarters · filed 2023-11-01 | |
| 2022-06-30 | -$27.37M 10-Q · filed 2023-11-01 | -$56.84M 10-Q · filed 2023-08-03 | -$89.68M derived: sum of 3 quarters · filed 2023-11-01 | -$120.37M derived: sum of 4 quarters · filed 2023-11-01 | |
| 2022-03-31 | -$29.46M 10-Q · filed 2023-11-01 | -$62.31M derived: sum of 2 quarters · filed 2023-11-01 | -$92.99M derived: sum of 3 quarters · filed 2023-11-01 | -$119.86M derived: sum of 4 quarters · filed 2023-11-01 | |
| 2021-12-31 | -$32.84M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | -$63.53M derived: sum of 2 quarters · filed 2023-03-15 | -$90.39M derived: sum of 3 quarters · filed 2023-03-15 | -$111.69M 10-K · filed 2023-03-15 | |
| 2021-09-30 | -$30.69M 10-Q · filed 2022-11-14 | -$57.55M derived: sum of 2 quarters · filed 2022-11-14 | -$78.85M 10-Q · filed 2022-11-14 | -$98.10M derived: sum of 4 quarters · filed 2022-11-14 | |
| 2021-06-30 | -$26.86M 10-Q · filed 2022-11-14 | -$48.16M 10-Q · filed 2022-08-09 | -$67.42M derived: sum of 3 quarters · filed 2022-11-14 | -$84.17M derived: sum of 4 quarters · filed 2022-11-14 | |
| 2021-03-31 | -$21.30M 10-Q · filed 2022-11-14 | -$40.55M derived: sum of 2 quarters · filed 2022-11-14 | -$57.31M derived: sum of 3 quarters · filed 2022-11-14 | -$68.72M derived: sum of 4 quarters · filed 2022-11-14 | |
| 2020-12-31 | -$19.25M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | -$36.01M derived: sum of 2 quarters · filed 2022-03-17 | -$47.42M derived: sum of 3 quarters · filed 2022-03-17 | -$56.93M 10-K · filed 2022-03-17 | |
| 2020-09-30 | -$16.76M 10-Q · filed 2021-11-12 | -$28.17M derived: sum of 2 quarters · filed 2021-11-12 | -$37.68M 10-Q · filed 2021-11-12 | -$47.72M derived: sum of 4 quarters · filed 2021-11-12 | |
| 2020-06-30 | -$11.41M 10-Q · filed 2021-11-12 | -$20.92M 10-Q · filed 2021-08-12 | -$30.96M derived: sum of 3 quarters · filed 2021-11-12 | -$37.69M derived: sum of 4 quarters · filed 2021-11-12 | |
| 2020-03-31 | -$9.51M 10-Q · filed 2021-11-12 | -$19.55M derived: sum of 2 quarters · filed 2021-11-12 | -$26.28M derived: sum of 3 quarters · filed 2021-11-12 | -$31.84M derived: sum of 4 quarters · filed 2021-11-12 | |
| 2019-12-31 | -$10.04M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16 | -$16.77M derived: sum of 2 quarters · filed 2021-03-16 | -$22.33M derived: sum of 3 quarters · filed 2021-03-16 | -$27.57M 10-K · filed 2021-03-16 | |
| 2019-09-30 | -$6.73M 10-Q · filed 2020-11-10 | -$12.29M derived: sum of 2 quarters · filed 2020-11-10 | -$17.53M 10-Q · filed 2020-11-10 | ||
| 2019-06-30 | -$5.56M 10-Q · filed 2020-11-10 | -$10.80M derived: sum of 2 quarters · filed 2020-11-10 | |||
| 2019-03-31 | -$5.24M 10-Q · filed 2020-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |